UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Value in health, ISSN 1098-3015, 10/2017, Volume 20, Issue 9, p. A889
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2222 - 2234
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycopyrrolate - adverse effects | Indans - adverse effects | Pulmonary Disease, Chronic Obstructive - mortality | Glucocorticoids - therapeutic use | Double-Blind Method | Glycopyrrolate - therapeutic use | Humans | Middle Aged | Administration, Inhalation | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Fluticasone-Salmeterol Drug Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Indacaterol | Dosage and administration | Salmeterol | Respiratory therapy | Acetylcholine receptors (muscarinic) | Glucocorticoids | Lung diseases | Fluticasone | Preventive medicine | Patients | Inhalation | Obstructive lung disease | Comparative studies | Chronic obstructive pulmonary disease | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Respirology (Carlton, Vic.), ISSN 1323-7799, 11/2017, Volume 22, Issue S3, pp. 176 - 177
Journal Article
Respirology (Carlton, Vic.), ISSN 1323-7799, 11/2017, Volume 22, Issue S3, pp. 178 - 178
Journal Article
Luminescence (Chichester, England), ISSN 1522-7235, 08/2018, Volume 33, Issue 5, pp. 913 - 918
coumarin derivatives | spectrofluorimetry, salmeterol xinafoate | human plasma | pharmaceutical analysis | Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Fluorescent Dyes - chemical synthesis | Fluorescent Dyes - chemistry | Spectrometry, Fluorescence - methods | Limit of Detection | Reproducibility of Results | Temperature | Solvents - chemistry | Humans | Coumarins - chemistry | Sulfuric Acids - chemistry | Salmeterol Xinafoate - analysis | Time Factors | Salmeterol Xinafoate - blood | Salmeterol Xinafoate - chemistry | Pharmaceutical Preparations | Acetoacetates - chemistry | Analysis | Methods | Salmeterol | Drugs | Correlation coefficient | Analytical methods | Regulatory agencies | Methodology | Correlation coefficients | Fluorescence | Firmness | Quantitation | Phenolic compounds | Coumarin | Recovery | Blood plasma | Salmeterol xinafoate | Mathematical analysis | Phenols | Detection | Chemical synthesis | Pharmaceuticals | Index Medicus
Journal Article
Pharmaceutical research, ISSN 0724-8741, 1/2019, Volume 36, Issue 1, pp. 1 - 14
Biochemistry, general | bipolar next generation impactor | pressurized metered dose inhaler | Biomedicine | Pharmacy | Bipolar charge | Medical Law | electrostatic charge | Pharmacology/Toxicology | Biomedical Engineering and Bioengineering | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Suspensions - chemistry | Fluticasone - chemistry | Fluticasone-Salmeterol Drug Combination - chemistry | Administration, Inhalation | Aerosols - chemistry | Static Electricity | Equipment Design | Technology, Pharmaceutical - instrumentation | Chemistry, Pharmaceutical - instrumentation | Particle Size | Powders - chemistry | Salmeterol Xinafoate - chemistry | Surface Properties | Metered Dose Inhalers | Measurement | Bipolar disorder | Fluticasone | Clouds | Salmeterol | Resveratrol | Propionic acid | Crystals | Particulates | Ice | Charge distribution | Electrostatic precipitators | Ice formation | Salmeterol xinafoate | Ice crystals | Ratios | Aerosols | Precipitators | Inhalers | Charged particles | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 9, pp. 840 - 849
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Bronchodilator Agents - administration & dosage | Double-Blind Method | Humans | Proportional Hazards Models | Administration, Inhalation | Child, Preschool | Male | Asthma - drug therapy | Fluticasone-Salmeterol Drug Combination - administration & dosage | Fluticasone-Salmeterol Drug Combination - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Fluticasone - administration & dosage | Adrenergic beta-1 Receptor Agonists - administration & dosage | Metered Dose Inhalers | Adrenergic beta-2 Receptor Agonists - administration & dosage | Female | Adrenergic beta-1 Receptor Agonists - adverse effects | Bronchodilator Agents - adverse effects | Child | Delayed-Action Preparations | Fluticasone - adverse effects | Usage | Children | Steroids (Drugs) | Health aspects | Risk factors | Asthma | Respiratory therapy | Pediatrics | Glucocorticoids | Propionic acid | Salmeterol | Fluticasone | Patients | Children & youth | Meta-analysis | Patient safety | Intubation | Safety | Index Medicus | Abridged Index Medicus
Journal Article
European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, 10/2015, Volume 96, pp. 132 - 142
Salmeterol xinafoate | Fixed dose combination | Mometasone furoate | Brittle matrix powder | Thin-film freezing | Co-deposition | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Mometasone Furoate - administration & dosage | Administration, Inhalation | Salmeterol Xinafoate - pharmacokinetics | Male | Salmeterol Xinafoate - administration & dosage | Rats, Sprague-Dawley | Chemistry, Pharmaceutical | Drug Delivery Systems | Particle Size | Tissue Distribution | Animals | Excipients - chemistry | Microscopy, Electrochemical, Scanning | X-Ray Diffraction | Salmeterol Xinafoate - chemistry | Surface Properties | Drug Compounding | Calorimetry, Differential Scanning | Female | Lung - metabolism | Bronchoalveolar Lavage Fluid - chemistry | Mometasone Furoate - chemistry | Mometasone Furoate - pharmacokinetics | Drug Combinations | Drugs | Drug delivery systems | Mometasone | Salmeterol | Vehicles | Steroids | Index Medicus
Journal Article
The European respiratory journal, ISSN 0903-1936, 10/2017, Volume 50, Issue 4, pp. 1700451 - 1700451
Life Sciences & Biomedicine | Respiratory System | Science & Technology | Sputum - microbiology | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Pulmonary Disease, Chronic Obstructive - microbiology | Humans | Middle Aged | Male | Drug Monitoring - methods | Salmeterol Xinafoate - adverse effects | Bacterial Load - drug effects | Forced Expiratory Volume | Respiratory Tract Infections - microbiology | Long Term Adverse Effects - microbiology | Pulmonary Disease, Chronic Obstructive - blood | Bacterial Load - methods | Female | Eosinophils - pathology | Bronchodilator Agents - adverse effects | Fluticasone - adverse effects | Glucocorticoids - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Administration, Inhalation | Treatment Outcome | Salmeterol Xinafoate - administration & dosage | Respiratory Tract Infections - diagnosis | Long Term Adverse Effects - diagnosis | Fluticasone - administration & dosage | Respiratory Function Tests | Viral Load - drug effects | Viral Load - methods | Pulmonary Disease, Chronic Obstructive - drug therapy | Respiratory therapy | Corticoids | Leukocytes (eosinophilic) | Propionic acid | Salmeterol | Microbiomes | Inflammation | Fluticasone | Inhalation | Respiratory tract | Sputum | Bacteria | Chronic obstructive pulmonary disease | Long-term effects
Journal Article
Biopharmaceutics & drug disposition, ISSN 0142-2782, 10/2017, Volume 38, Issue 7, pp. 407 - 419
parallel absorption | salmeterol xinafoate | dry powder inhalers | population pharmacokinetics | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Adrenergic beta-2 Receptor Agonists - pharmacokinetics | Bronchodilator Agents - blood | Asthma - metabolism | Dry Powder Inhalers | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Administration, Inhalation | Salmeterol Xinafoate - pharmacokinetics | Male | Salmeterol Xinafoate - administration & dosage | Cross-Over Studies | Young Adult | Adrenergic beta-2 Receptor Agonists - blood | Salmeterol Xinafoate - blood | Bronchodilator Agents - pharmacokinetics | Adrenergic beta-2 Receptor Agonists - administration & dosage | Adult | Female | Therapeutic Equivalency | Powders | Inhalers | Analysis | Asthma | Body weight | Salmeterol | Data processing | Population studies | Pharmacology | Patients | Powder | Absorption | Lungs | Activated carbon | Pharmacokinetics | Activated charcoal | Charcoal | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 14, pp. 1285 - 1294
ISOLDE | OBSTRUCTIVE PULMONARY-DISEASE | FLUTICASONE PROPIONATE | PREVENTION | TIOTROPIUM | RANDOMIZED CONTROLLED-TRIAL | CORTICOSTEROIDS | SALMETEROL | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Chronic obstructive pulmonary disease, asthma | Pneumology | Spirometry | Glucocorticoids - administration & dosage | Salmeterol Xinafoate | Bronchodilator Agents - administration & dosage | Double-Blind Method | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Proportional Hazards Models | Administration, Inhalation | Albuterol - analogs & derivatives | Male | Fluticasone | Withholding Treatment | Androstadienes - administration & dosage | Albuterol - administration & dosage | Scopolamine Derivatives - administration & dosage | Female | Aged | Drug Therapy, Combination | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Lung diseases, Obstructive | Care and treatment | Corticosteroids | Research | Patient outcomes | Respiratory therapy | Respiratory function | Glucocorticoids | Medical treatment | Propionic acid | Lung diseases | Salmeterol | Patients | Dyspnea | Obstructive lung disease | Bronchodilators | Chronic obstructive pulmonary disease | Respiration | Index Medicus | Abridged Index Medicus | Case studies | Estudi de casos | Malalties pulmonars obstructives cròniques | Corticosteroides | Chronic obstructive pulmonary diseases | Adrenocortical hormones
Journal Article